HANXBIO-B repurchases 68,800 H shares for HKD 1.82 million

Bulletin Express06-09

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 9 June 2026 it repurchased 68,800 H shares on the Hong Kong Stock Exchange, paying a total of HKD 1.82 million. The buy-back was executed at prices ranging between HKD 25.72 and HKD 27.56, translating to a volume-weighted average cost of HKD 26.49 per share. All repurchased shares are being held as treasury stock.

Following the transaction, outstanding shares (excluding treasury stock) fell to 135.04 million, while treasury shares increased to 1.18 million. Total issued share capital remains unchanged at 136.22 million.

The repurchase forms part of a mandate approved on 12 February 2026 authorising the company to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 1.18 million shares, representing 0.86 % of the shares outstanding on the mandate date.

Under Hong Kong listing rules, Hanx Biopharmaceuticals is restricted from issuing, selling or transferring shares until 9 July 2026, 30 days after the latest buy-back.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124764548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124764548","market":"us","top_or_hot":-1,"title":"HANXBIO-B repurchases 68,800 H shares for HKD 1.82 million","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 9 June 2026 it repurchased 68,800 H shares on the Hong Kong Stock Exchange, paying a total of HKD 1.82 million. The buy-back was executed at prices ranging between HKD 25.72 and HKD 27.56, translating to a volume-weighted average cost of HKD 26.49 per share. All repurchased shares are being held as treasury stock.</p>\n<p>Following the transaction, outstanding shares (excluding treasury stock) fell to 135.04 million, while treasury shares increased to 1.18 million. Total issued share capital remains unchanged at 136.22 million.</p>\n<p>The repurchase forms part of a mandate approved on 12 February 2026 authorising the company to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 1.18 million shares, representing 0.86 % of the shares outstanding on the mandate date.</p>\n<p>Under Hong Kong listing rules, Hanx Biopharmaceuticals is restricted from issuing, selling or transferring shares until 9 July 2026, 30 days after the latest buy-back.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B repurchases 68,800 H shares for HKD 1.82 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B repurchases 68,800 H shares for HKD 1.82 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-09 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 9 June 2026 it repurchased 68,800 H shares on the Hong Kong Stock Exchange, paying a total of HKD 1.82 million. The buy-back was executed at prices ranging between HKD 25.72 and HKD 27.56, translating to a volume-weighted average cost of HKD 26.49 per share. All repurchased shares are being held as treasury stock.</p>\n<p>Following the transaction, outstanding shares (excluding treasury stock) fell to 135.04 million, while treasury shares increased to 1.18 million. Total issued share capital remains unchanged at 136.22 million.</p>\n<p>The repurchase forms part of a mandate approved on 12 February 2026 authorising the company to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 1.18 million shares, representing 0.86 % of the shares outstanding on the mandate date.</p>\n<p>Under Hong Kong listing rules, Hanx Biopharmaceuticals is restricted from issuing, selling or transferring shares until 9 July 2026, 30 days after the latest buy-back.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1124764548","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124764548","pubTimestamp":1781005394,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 9 June 2026 it repurchased 68,800 H shares on the Hong Kong Stock Exchange, paying a total of HKD 1.82 million. The buy-back was executed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉思生物-B以182万港元回购6.88万股H股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 9 June 2026 it repurchased 68,800 H shares on the Hong Kong Stock Exchange, paying a total of HKD 1.82 million. The buy-back was executed at prices ranging between HKD 25.72 and HKD 27.56, translating to a volume-weighted average cost of HKD 26.49 per share. All repurchased shares are being held as treasury stock.\nFollowing the transaction, outstanding shares (excluding treasury stock) fell to 135.04 million, while treasury shares increased to 1.18 million. Total issued share capital remains unchanged at 136.22 million.\nThe repurchase forms part of a mandate approved on 12 February 2026 authorising the company to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 1.18 million shares, representing 0.86 % of the shares outstanding on the mandate date.\nUnder Hong Kong listing rules, Hanx Biopharmaceuticals is restricted from issuing, selling or transferring shares until 9 July 2026, 30 days after the latest buy-back.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124764548","isCrawlerRequest":true}